促红素衍生修复肽 Ara-290 / Cibinetide

ARA-290 is a synthetic 11-amino acid peptide engineered from the B-helix domain of erythropoietin (EPO) — the hormone your kidneys make to drive red blood cell production. The problem with EPO itself is that its tissue-protective effects come bundled with serious risks: blood thickening, clot formation, and in cancer patients, potential tumor growth. ARA-290 was designed to separate those two functions. It keeps the tissue-protective, anti-inflammatory signaling and strips out the erythropoiesis entirely.

That separation is what makes it scientifically interesting. The compound targets a specific receptor complex — EPOR–CD131, sometimes called the innate repair receptor (IRR) — that mediates EPO's protective effects on injured tissue, peripheral nerves, and the immune system, without touching the classical EPO receptor that drives red blood cell production.^[1] If that distinction holds up in larger trials, ARA-290 could offer a way to harness EPO's neuroprotective potential without the hematological risks that have made EPO itself too dangerous for routine use in non-anemic patients.

Right now, ARA-290 is a research-only compound. It has completed Phase 2 trials in type 2 diabetes with neuropathy and in sarcoidosis-associated small fiber neuropathy, with genuinely promising results in both. But it has no FDA approval, no approved commercial form, and no legal pathway for clinical use outside of an enrolled research study.

Key Takeaways

• ARA-290 is engineered from erythropoietin's B-helix domain specifically to preserve tissue-protective effects while eliminating the red blood cell stimulation that makes full EPO dangerous.

It targets the EPOR–CD131 innate repair receptor complex, activating anti-inflammatory and neuroprotective pathways without erythropoietic activity.

A Phase 2 trial in type 2 diabetes with painful neuropathy showed improvements in both metabolic control and neuropathic symptoms at a 4 mg subcutaneous dose.

ARA-290 is research-only — no FDA approval, no compounding pharmacy access, no legal commercial pathway in the US.

The most clinically developed application is small fiber neuropathy, particularly in sarcoidosis patients, where few effective treatments currently exist.

Class	Erythropoietin-derived tissue-protective peptide
Amino Acids	11 (B-helix domain fragment of EPO)
Mechanism	EPOR–CD131 (innate repair receptor) agonism; non-erythropoietic
FDA Status	Research only — not approved
Administration	Subcutaneous injection (lyophilized powder for research use)
Typical Dose (Trial Range)	4 mg subcutaneous, once daily for 28 days (Phase 2 trial)
Half-life	Not established in human clinical studies
Primary Research Areas	Neuropathic pain, small fiber neuropathy, type 2 diabetes, neuroinflammation

---

There are no FDA-approved dosing guidelines for ARA-290. The figures below come directly from published clinical research.

Research dosing only

ARA-290 has no established clinical dose. The numbers below are what researchers used in Phase 2 trials. They are not prescriptive medical guidance and should not be used as a self-administration reference.

The Phase 2 trial in type 2 diabetes with painful neuropathy used a fixed dose of 4 mg administered subcutaneously once daily for 28 consecutive days.^[2] That's the most rigorously documented human dosing protocol available. Participants self-administered the injections, which is notable — it suggests the administration protocol was considered manageable outside a clinical setting, though all participants were under active study monitoring.

Animal studies have used variable dosing depending on the model and endpoint, but those figures don't translate directly to human use and aren't listed here given the lack of a reliable conversion basis.

4 mg/day × 28 days subcutaneous dose used in the Phase 2 diabetes-neuropathy trial — the only published human dosing protocol

The sarcoidosis-associated small fiber neuropathy research also examined ARA-290 dosing in a clinical context,^[3] but detailed dose-response data across multiple dose levels in humans has not been published in the references available here. We don't yet know whether doses higher or lower than 4 mg produce meaningfully different outcomes in humans — that data either hasn't been collected or hasn't been published.

---

Most approaches to neuropathic pain target the pain signal itself — opioids, gabapentinoids, SNRIs. They dampen what you feel. ARA-290 is trying to do something more fundamental: address the underlying tissue injury and neuroinflammation that's generating the pain in the first place.

That's the core of its appeal. And it's why the sarcoidosis application is particularly interesting. Sarcoidosis-associated small fiber neuropathy is notoriously hard to treat. It causes severe neuropathic pain and autonomic dysfunction from damage to small and autonomic nerve fibers, and current treatments have limited efficacy.^[3] Patients with this condition often cycle through medications that blunt symptoms without addressing the nerve damage itself. ARA-290's mechanism — tissue protection and repair signaling through the innate repair receptor — is at least theoretically aimed at the right target.

Why EPO itself doesn't work here

Full erythropoietin has shown tissue-protective and neuroprotective effects in animal models, but clinical use in non-anemic patients is dangerous. EPO thickens the blood, raises clot risk, and in some cancer contexts may stimulate tumor growth. ARA-290 was engineered specifically to isolate the protective signaling through the EPOR–CD131 complex while leaving the classical EPO receptor — the one that drives red blood cell production — largely unengaged. That's the entire design rationale.

The TRPV1 channel research adds another layer. A 2016 study found that ARA-290's analgesic effects may involve direct targeting of TRPV1 — a peripheral pain receptor involved in heat and inflammatory pain signaling — in addition to its anti-inflammatory effects through the IRR.^[4] If both mechanisms are real and additive, that's a more complete picture of how the compound works than the IRR story alone.

---

Start with erythropoietin. EPO is best known as the hormone that tells your bone marrow to make more red blood cells — which is why athletes have abused it for decades and why it's tightly regulated. But EPO also binds a second receptor complex, EPOR–CD131, that has nothing to do with blood production. This complex — sometimes called the innate repair receptor, or IRR — mediates tissue protection, anti-inflammatory signaling, and nerve repair responses.^[1]

ARA-290 is a short 11-amino acid peptide taken from the B-helix region of EPO's three-dimensional structure. That specific region is what interacts with the IRR. By isolating it, researchers created a compound that activates the IRR pathway without meaningfully engaging the classical EPO receptor that drives erythropoiesis.^[2]

What does IRR activation actually do? Downstream signaling through EPOR–CD131 suppresses pro-inflammatory cytokine activity, reduces microglial activation in the spinal cord, and promotes tissue repair responses in damaged peripheral nerves.^[5] In plain terms: it turns down the inflammatory response that both causes and sustains nerve damage, while promoting the cellular environment needed for repair.

The TRPV1 angle adds specificity at the pain receptor level. TRPV1 channels are expressed on peripheral nociceptors — the nerve endings that detect pain, heat, and inflammation. Research suggests ARA-290 may directly modulate TRPV1 activity, reducing its sensitization in inflamed tissue.^[4] This would explain why pain relief in animal models appears fairly rapid, and why the analgesic effects seem to outlast the period of active dosing in some studies.

One more piece: the monocyte connection. A 2022 study in an Alzheimer's disease mouse model found that early treatment with ARA-290 modulated monocyte immune function and slowed amyloid-β pathology progression.^[6] Monocytes are peripheral immune cells that can migrate into the brain and influence neuroinflammation. This is early-stage animal data, but it opens a potential application in neurodegeneration that's worth watching.

---

The most important human data comes from the Phase 2 trial published in 2015 in Molecular Medicine.^[2] This was a randomized, placebo-controlled study in patients with type 2 diabetes and painful neuropathy. Participants received 4 mg of ARA-290 or placebo subcutaneously once daily for 28 days, then were followed for an additional period after dosing stopped.

The results were notable on two fronts. First, metabolic: ARA-290-treated patients showed improvements in HbA1c — a 90-day average of blood glucose control — compared to placebo. Second, neuropathic: participants reported meaningful reductions in neuropathic pain symptoms. The study also found improvements in intraepidermal nerve fiber density, which is a structural measure of small fiber nerve integrity, not just a symptom report.^[2] That's harder to fake with placebo effects.

The sarcoidosis application is documented in a 2014 review in Expert Opinion on Investigational Drugs, which outlines the rationale for using ARA-290 in sarcoidosis-associated small fiber neuropathy — a condition where the IRR pathway is a plausible therapeutic target given the inflammatory nature of the underlying disease.^[3]

The animal and preclinical data on neuropathic pain is more extensive. A 2014 study in Molecular Pain demonstrated dose-dependent pain relief in a neuropathic pain model, coupled with measurable suppression of spinal cord microglial activation.^[5] That microglial suppression is significant — spinal microglia are a key driver of central sensitization, the process by which the nervous system amplifies pain signals after injury. Pain relief that outlasted the dosing period was also documented in that study, suggesting some durable effect on the underlying inflammatory state rather than simple symptomatic masking.

What We Don't Know Yet

• Long-term safety — The Phase 2 trial ran 28 days. We have no data on what happens with repeated or extended use in humans.
• Dose-response in humans — Only one dose (4 mg) has been tested in published human trials. Whether lower doses work or higher doses work better is unknown.
• Mechanism confirmation — The TRPV1 interaction and monocyte modulation data come from animal or cell studies. Human confirmation is absent.
• Phase 3 data — No Phase 3 trial results are available. We don't know if the Phase 2 signals will replicate in larger populations.
• Alzheimer's application — The 2022 monocyte/AD data is mouse model only.^[6] This is preclinical hypothesis generation, not clinical evidence.
• Comparative efficacy — No head-to-head trials against existing neuropathic pain treatments (gabapentin, duloxetine, pregabalin) exist.

---

Human safety data for ARA-290 is limited to small Phase 2 trials. The 2015 diabetes-neuropathy study reported no serious adverse events attributable to ARA-290 at the 4 mg dose over 28 days of daily subcutaneous administration.^[2] That's a meaningful signal, but the sample size was small enough that rarer adverse events wouldn't necessarily appear.

What the Phase 2 trial documented:

• No serious adverse events — reported at 4 mg/day over 28 days in the published trial population.^[2]
• Injection site reactions — common with any subcutaneous peptide; the trial used self-administration, suggesting tolerability was acceptable, but specific incidence data isn't reported in the available abstracts.

What we don't have data on:

• Longer-term effects — 28 days is a short window. Chronic administration safety is unstudied in humans.
• Cardiovascular effects — Full EPO raises hematocrit and clot risk. ARA-290 is designed to avoid this, but long-term cardiovascular monitoring data in humans doesn't exist.
• Drug interactions — No published interaction data is available.

If you're a researcher or clinician evaluating ARA-290, the absence of serious adverse events in Phase 2 is encouraging but not a clean bill of safety. The compound is non-erythropoietic by design, which removes EPO's most dangerous known risk, but that design principle has only been validated in short-duration small trials.

---

ARA-290 — Research Only, No Legal Commercial Pathway

ARA-290 has no FDA approval and no approved indication. It is not available through licensed compounding pharmacies, telehealth clinics, or commercial peptide vendors in the US. Legal access is limited to enrolled participants in clinical research studies. If you encounter ARA-290 being sold commercially, it is operating outside FDA regulatory boundaries.

ARA-290 carries a research-only designation. The FDA has not approved it for any indication, and it has not completed the Phase 3 trials that would be required for an NDA submission. Its current regulatory status means it can be used in IRB-approved clinical research with appropriate oversight, but not prescribed or dispensed in a clinical practice setting.

The FDA has taken enforcement action against companies marketing unapproved peptide products broadly. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity relevant to research peptides.

For anyone interested in access through legitimate channels: ClinicalTrials.gov is the right starting point. Search for "ARA-290" or "innate repair receptor" to find any currently enrolling studies. That is the only legal route to human exposure in the US.

---

ARA-290's closest conceptual relatives are other tissue-protective, non-erythropoietic EPO derivatives — a small and mostly preclinical class. If you're researching neuroprotective peptides more broadly, BPC-157 is the most clinically discussed compound in the tissue-repair space, though its mechanism (primarily through growth hormone receptor and nitric oxide pathways) is distinct from ARA-290's IRR-mediated approach. Thymosin Beta-4 is another peptide studied for tissue repair and anti-inflammatory effects, with some overlap in the neuroinflammation research space.

For painful neuropathy specifically, the comparison that matters most isn't between peptides — it's between ARA-290 and standard-of-care pharmacology: gabapentin, pregabalin, duloxetine, and SNRIs. None of those have direct head-to-head data against ARA-290, and given that ARA-290 is still investigational, a direct comparison isn't possible yet. What's distinct about ARA-290's approach is the structural evidence of nerve fiber repair, not just symptom reduction — if that finding replicates in Phase 3, it changes the nature of the comparison.

---